PDAC

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Retrieved on: 
Tuesday, April 9, 2024
Mutation, Growth, NSCLC, Colorectal cancer, RAS, Patient, Research, PDAC, Lung cancer, GTP, AACR, Clinical trial, Cancer, CRC, G13, G12, Pharmaceutical industry

This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.

Key Points: 
  • This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.
  • Oncogenic RAS proteins drive up to 30 percent of all human cancers, most notably non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC).
  • RAS G12 mutations, such as G12D, G12V and G12C, predominate in human cancers.
  • The paper describes the discovery of RMC-6236, an oral, multi-selective inhibitor of the active GTP-bound (ON) state of both mutant and wild-type RAS.

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Annual, Conference, Significance, Patient, Standard of care, Șaeș, PDAC, Toxicity, AACR, Survivor, Pancreatic cancer, Therapy, Infrared spectroscopy correlation table, SAE, Medicine, Pharmaceutical industry

CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experience with a novel first-in-class G-Quadruplex experimental anti-cancer drug, QN-302, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.

Key Points: 
  • CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experience with a novel first-in-class G-Quadruplex experimental anti-cancer drug, QN-302, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.
  • Dose escalation initiated (patient #101-004) after three patients successfully completed cycle 1 of the initial dose.
  • Dose escalation will be continued, with more patients being enrolled in the coming months.
  • One patient was withdrawn from study 3/1/2024 after 4 months of stable disease.

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Retrieved on: 
Monday, April 8, 2024
NSCLC, Colorectal cancer, CYPA, RAS, Patient, Research, PDAC, Lung cancer, Protein, Trial of the century, GTP, Cancer, CRC, Pharmacology, Ras GTPase, Drug resistance, Pharmaceutical industry

REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of two peer-reviewed research papers in Nature. The first paper highlights the discovery and preclinical characterization of RMC-7977, a preclinical tool compound representative of a class of oral RAS(ON) multi-selective inhibitors, including the investigational drug candidate RMC-6236, that target multiple RAS variants. The second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC. This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.

Key Points: 
  • The first paper highlights the discovery and preclinical characterization of RMC-7977, a preclinical tool compound representative of a class of oral RAS(ON) multi-selective inhibitors, including the investigational drug candidate RMC-6236, that target multiple RAS variants.
  • The second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC.
  • This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.
  • Oncogenic RAS proteins drive up to 30 percent of all human cancers, most notably non-small cell lung cancer (NSCLC), PDAC and colorectal cancer (CRC).

Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Combination, Irinotecan, Patient, Gene, FOLFIRINOX, Oncolytic adenovirus, Cancer, PDAC, Society, Therapy, Cell, Pharmaceutical industry

Data will be featured in a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) 27th Annual Meeting, being held both virtually and in Baltimore from May 7-11, 2024.

Key Points: 
  • Data will be featured in a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) 27th Annual Meeting, being held both virtually and in Baltimore from May 7-11, 2024.
  • “We look forward to presenting data at the upcoming ASGCT meeting that further highlight the potential of our systemically administered oncolytic adenovirus, VCN-01, to synergistically combine with an expanding range of standard-of-care chemotherapies for difficult-to-treat cancers,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
  • “ Our on-going VIRAGE Phase 2b trial is evaluating VCN-01 in combination with gemcitabine/nab-paclitaxel to treat metastatic pancreatic ductal adenocarcinoma (PDAC).
  • ET

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

Retrieved on: 
Sunday, April 7, 2024
BNTX, Survival, Entrepreneurship, Genentech, Disease, BioNTech, Patient, Neoplasm, Tissue, Messenger, PDAC, Roche, Uridine, Safety, Cancer, De novo, Recurrence, Blood, Vaccine

The data show that in 8 out of 16 patients autogene cevumeran elicited an immune response up to three years post administration measured by activated T cells.

Key Points: 
  • The data show that in 8 out of 16 patients autogene cevumeran elicited an immune response up to three years post administration measured by activated T cells.
  • The persistence of T cels was associated with a longer median recurrence-free survival in cancer vaccine responders.
  • “These new data are an early signal for the potential of our individualized mRNA cancer vaccine approach in this indication with an unmet medical need.
  • Over 80% of the vaccine-induced neoantigen-specific T cells could still be detected up to three years post administration in patients with an immune response.

METC extended through March 31, 2025

Retrieved on: 
Tuesday, April 2, 2024
PDAC, Natural Resources, FTS, Government, Metal, News, METC, Mining

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- The Government of Canada announced an extension to the Mineral Exploration Tax Credit (METC) through March 31, 2025.

Key Points: 
  • TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- The Government of Canada announced an extension to the Mineral Exploration Tax Credit (METC) through March 31, 2025.
  • The extension represents $65 million to support investment in domestic mineral exploration and will generate multi-fold economic impacts in many regions and communities across the country.
  • The METC is a made-in-Canada financial incentive that provides flow-through share (FTS) investors with an additional 15% non-refundable tax credit when funds are directed towards greenfield exploration.
  • According to the Government of Canada, the METC supported over 300 companies to raise equity by issuing eligible flow-through shares to more than 12,400 investors in 2021 alone.

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Research, Week, CD135, Administration, FMS, Growth, Menin, CLL, NSCLC, C-peptide, AML, BID, Diabetes, Insulin, Patient, Hypoglycemia, FLT3, G&A, Acute myeloid leukemia, Food, PDAC, Health Canada, Trial of the century, IND, Cancer, CRC, Safety, Research and development, Investment, FDA, DLBCL, DSM-IV codes, Pharmaceutical industry

In 2023, initiated a Phase 2 study of BMF-219 in type 1 diabetes patients (COVALENT-112); initial readout anticipated in 2024.

Key Points: 
  • In 2023, initiated a Phase 2 study of BMF-219 in type 1 diabetes patients (COVALENT-112); initial readout anticipated in 2024.
  • Cash position of $177.2 million at the end of the fourth quarter of 2023.
  • REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, reported fourth quarter and full year 2023 financial results and corporate highlights.
  • “2023 was a pivotal year for Biomea as we reported first positive data in type 2 diabetes and initiated our first clinical study in type 1 diabetes.

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Friday, March 29, 2024
PDAC, Completeness, Patient, Neoplasm, DNA, RFS, Therapy, Cancer, Pharmaceutical industry

BOSTON, March 29, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX,“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ending December 31, 2023, and provided recent business highlights.

Key Points: 
  • BOSTON, March 29, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX,“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ending December 31, 2023, and provided recent business highlights.
  • The independent data monitoring committee completed the safety review of ELI-002 7P Phase 1 trial patients and confirmed the recommended Phase 2 trial dose.
  • No safety concerns were identified, and no dose limiting toxicities and no ≥ grade 3 treatment related adverse events were observed.
  • Cash and cash equivalents as of December 31, 2023, were $12.9 million, compared to $6.2 million as of December 31, 2022.

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Retrieved on: 
Thursday, March 21, 2024
Research, Common stock, Ovarian cancer, IHC, Head, Therapeutic index, NSCLC, Immunotherapy, HNSCC, Patient, Neoplasm, Cohort, Tumor microenvironment, Observation, DESC, PDAC, Lung cancer, DLT, Investment, Clinical trial, Cancer, PIPE, ATM, Safety, Pharmacokinetics, Therapy, ADC, FACT, Pharmaceutical industry

BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the year and quarter ended December 31, 2023, and provided a corporate update.

Key Points: 
  • BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the year and quarter ended December 31, 2023, and provided a corporate update.
  • Approximately 54% of subjects have experienced grade 2, and 6% of subjects have experienced grade 3 treatment emergent adverse events (TEAEs).
  • As of December 31, 2023, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments of $120.8 million.
  • As of March 20, 2024, the outstanding number of shares of Common Stock of Pyxis Oncology was 58,133,375.

GeneCentric Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Monday, April 1, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Tempus, Survival, Colorectal cancer, Patient, RNA, MSI, FOLFIRINOX, PDAC, Medicine, Section 42, News, AACR, Microsatellite instability, Therapy, Cancer

GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.

Key Points: 
  • GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.
  • Presentations will include a poster describing a new colorectal cancer predictive response signature (MSS-PRS) that selects tumors not identified with conventional MSI testing but have molecular characteristics consistent with microsatellite instability, making them a potential target for immune checkpoint inhibition.
  • A second poster presentation describes ongoing clinical validation for PurISTSM, a novel RNA-expression test developed in collaboration with Tempus.
  • Details of the AACR presentations are as follows:
    Session: PO.CL01.01 – Diagnostic Biomarkers 1, Section 42
    The posters will be accessible under the News & Events section of the Company’s website following the conference.